Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cyclophosphamide/doxorubicin/paclitaxel

Cyclophosphamide/doxorubicin/paclitaxel Reactions 1680, p102 - 2 Dec 2017 Cyclophosphamide/doxorubicin/ paclitaxel Vitiligo: case report A woman in her 50s [exact age at reaction onset not stated] developed vitiligo during treatment with cyclophosphamide, doxorubicin [adriamycin] and paclitaxel. The woman had a history of hypothyroidism treated with thyroxine replacement therapy. She was diagnosed with breast cancer along with an axillary lymphadenopathy at the age of 58 years, and underwent left modified radical mastectomy. Subsequently, she received 4 cycles of chemotherapy with 2 2 cyclophosphamide 600 mg/m and doxorubicin 60 mg/m , followed by four cycles of paclitaxel 175 mg/m [routes not stated]. After completion of 24 week chemotherapy course, she was treated with an external beam radiotherapy to the left chest wall. Approximately nine months after radiotherapy, she was observed with a depigmentation on the left chest wall, which was congruent with area of radiation delivery. The hypopigmented lesions could be identified with sharp margins. The lesions were without a definite shape, which coalesced and persisted as evidenced in her successive follow- ups. At the last follow up, the woman was found to be well, though continued with hypopigmented lesions on the left chest, without any further regression or progression. Author comment: "It http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cyclophosphamide/doxorubicin/paclitaxel

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Download PDF
1 page

Cyclophosphamide/doxorubicin/paclitaxel

Abstract

Reactions 1680, p102 - 2 Dec 2017 Cyclophosphamide/doxorubicin/ paclitaxel Vitiligo: case report A woman in her 50s [exact age at reaction onset not stated] developed vitiligo during treatment with cyclophosphamide, doxorubicin [adriamycin] and paclitaxel. The woman had a history of hypothyroidism treated with thyroxine replacement therapy. She was diagnosed with breast cancer along with an axillary lymphadenopathy at the age of 58 years, and underwent left modified radical mastectomy....
Loading next page...
 
/lp/springer_journal/cyclophosphamide-doxorubicin-paclitaxel-CVv0EipURN

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-39033-8
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p102 - 2 Dec 2017 Cyclophosphamide/doxorubicin/ paclitaxel Vitiligo: case report A woman in her 50s [exact age at reaction onset not stated] developed vitiligo during treatment with cyclophosphamide, doxorubicin [adriamycin] and paclitaxel. The woman had a history of hypothyroidism treated with thyroxine replacement therapy. She was diagnosed with breast cancer along with an axillary lymphadenopathy at the age of 58 years, and underwent left modified radical mastectomy. Subsequently, she received 4 cycles of chemotherapy with 2 2 cyclophosphamide 600 mg/m and doxorubicin 60 mg/m , followed by four cycles of paclitaxel 175 mg/m [routes not stated]. After completion of 24 week chemotherapy course, she was treated with an external beam radiotherapy to the left chest wall. Approximately nine months after radiotherapy, she was observed with a depigmentation on the left chest wall, which was congruent with area of radiation delivery. The hypopigmented lesions could be identified with sharp margins. The lesions were without a definite shape, which coalesced and persisted as evidenced in her successive follow- ups. At the last follow up, the woman was found to be well, though continued with hypopigmented lesions on the left chest, without any further regression or progression. Author comment: "It

Journal

Reactions Weekly – Springer Journals

Published: Dec 2, 2017

There are no references for this article.